资源描述：
《索利那新治疗膀胱过度活动症疗效观察.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。
1、第24卷第6期中国现代医学杂志Vol.24No.62014年2月ChinaJournalofModernMedicineFeb.2014文章编号：1005-8982（2014）06-0101-03索利那新治疗膀胱过度活动症疗效观察袁道彰1，徐晓龙2，黄兰珍1，吴伟江1，苏泽轩3（1.广东省龙川县人民医院泌尿外科，广东龙川517300；2.华中科技大学同济医学院附属东莞医院泌尿外科，广东东莞523400；3.暨南大学附属第一医院泌尿外科，广东广州510630）摘要：目的评价索利那新治疗膀胱过度活动症的疗效及其安全性。方法将泌尿外科就诊的膀胱过度活动症的患者180例随机平分为试验组和对照组
2、，试验组给予索利那新每日1次，每次5mg，晚饭后口服，疗程6周；对照组给予托特罗定每日2次，每次2mg，早晚饭后口服，疗程6周。分别记录治疗前后24h的排尿次数、平均每次尿量、最大膀胱容量和最大尿流率，评价索利那新的疗效，通过主要不良反应发生率评价其安全性。结果试验组24h的排尿次数、平均尿量、最大膀胱容量和最大尿流率较对照组改善明显（P<0.05），试验组不良反应的发生率较对照组低（P<0.05）。结论索利那新治疗膀胱过度活动症疗效确切，安全性高。关键词：索利那新；托特罗定；膀胱过度活动症中图分类号：R694文献标识码：BEffectobservationofSolifenacini
3、ntreatingoveractivebladder12113YUANDao-zhang,XUXiao-long,HUANGLan-zhen,WUWei-jiang,SUZe-xuan(1.DepartmentofUrology,LongchuanPeople'sHospital,Longchuan,Guangdong517300,P.R.China;2.DepartmentofUrology,DongguanHospitalofTongjiMedicalCollegeofHuazhongScienceandTechnologyUniversity,Dongguan,Guangdong
4、523400,P.R.China;3.DepartmentofUrology,theFisrtAffiliatedHospitalofJinanUniversity,Guangzhou,Guangdong510630,P.R.China)Abstract:【Objective】ToevaluatetheefficacyandsafetyofSolifenacinintreatingpatientswithoveractiveblad－der(OAB).【Methods】Thestudywasarandomizedtrial.180patientswithOABwereenrolledi
5、ntheclinicaltrial,where90patientswereassignedtoreceiveSolifenacin(5mgoncedailyafterdinnerfor6weeks)and90wereas－signedtoreceivetoherodine(2mgtwicedailyafterbreakfastanddinnerfor6weeks).After6weeks'treatment,theimprovementofdailymicturitionfrequency,averageurineoutput,maximumcystometriccapacityand
6、maximumflowratewereusedtoevaluatetheefficacyofSolifenacin.WeevaluatedthesafetyofSolifenacinbycomparingtherateofadversedrugreactionsbetweenthetwogroups.【Results】Thedailymicturitionfrequency,averageurineoutput,maximumcystometriccapacityandmaximumflowrateweresignificantlyimprovedinthepatientswithOA
7、Breceiv－ingSolifenacin,ascomparedwiththepatientsreceivingToherodine(P<0.05).TherateofadversedrugreactionsinthepatientswithOABreceivingSolifenacinwerelowerthanthatinthepatientsreceivingToherodin(P<0.05).【Conclusions】Solifenac
